Illumina, Inc.
http://www.illumina.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Illumina, Inc.
Moderately Optimistic: Rounding Out Deal Making In 2024
Dealmaking trends in 2024 point toward a healthier financial ecosystem than in 2023. However, with a challenging three quarters in 2024, enthusiasm should be curbed as 2024 rounds out in a slow and steady manner.
News We’re Watching: Regulatory Clearances For Illumina, GE, Boston Scientific; FDA Patient Group To Meet In October; Johns Hopkins Joins AI Accelerator
This week, Illumina announced its new CDx has FDA approval; GE and Boston Scientific nabbed CE marks; and the FDA’s Patient Engagement Advisory Committee announced that its October meeting will focus on informed consent in clinical trials.
Stock Watch: Pfizer’s Q2 Windows Into Wider 2024 Issues
One company’s weak quarterly sales should not make a pharmaceutical winter. But combine the lower sales of major vaccine families across three companies’ portfolios with weak demand in China and it starts to feel chilly.
FTC Is Taking A Tougher Stance On Pharma, A Deputy Director Explains Why
Rahul Rao, the deputy director of the FTC Bureau of Competition, discussed the agency’s thinking on recent pharma deals that it viewed as anti-competitive.
Company Information
- Industry
- Pharmaceuticals
- Services
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Nanotechnology, Chips, etc.
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- GenoLogics Life Sciences Software
- GRAIL Inc.
- Myraqa
- Verinata Health
- Illumina Ventures
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice